LC
MRVI icon

Lindbrook Capital’s Maravai LifeSciences MRVI Stock Holding History

Lindbrook Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$2.73K Buy
1,237
+570
+85% +$2.25K ﹤0.01% 2187
2024
Q4 		$3.63K Sell
667
-937
-58% -$6.03K ﹤0.01% 2119
2024
Q3 		$13.3K Buy
1,604
+34
+2% +$294 ﹤0.01% 1523
2024
Q2 		$11.2K Buy
1,570
+832
+113% +$7.18K ﹤0.01% 1563
2024
Q1 		$6.4K Sell
738
-58
-7% -$392 ﹤0.01% 1789
2023
Q4 		$5.21K Buy
796
+379
+91% +$2.45K ﹤0.01% 1860
2023
Q3 		$4.17K Sell
417
-428
-51% -$4.7K ﹤0.01% 1841
2023
Q2 		$10.5K Sell
845
-89
-10% -$1.2K ﹤0.01% 1436
2023
Q1 		$13.1K Buy
934
+572
+158% +$8.21K ﹤0.01% 1288
2022
Q4 		$5.18K Buy
+362
New +$5.7K ﹤0.01% 1806

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's MRVI Position: Q1 2025 in Review

Lindbrook Capital increased its Maravai LifeSciences (MRVI) stake by 85% in Q1 2025, buying an estimated $2.25K and bringing the position to 1,237 shares worth $2.73K. The position accounts for ﹤0.01% of the portfolio, ranked #2187.

Lindbrook Capital first reported a position in MRVI in Q4 2022 and has held it in 10 quarters since. The position peaked at $13.3K in Q3 2024. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

  • Lindbrook Capital held 1,237 shares of Maravai LifeSciences worth $2.73K as of Q1 2025.
  • Lindbrook Capital bought 570 Maravai LifeSciences shares in Q1 2025, an estimated $2.25K.
  • Maravai LifeSciences made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2187 holding.
  • Lindbrook Capital first reported a position in Maravai LifeSciences in Q4 2022 and has held it in 10 quarters since.
  • Lindbrook Capital's Maravai LifeSciences position peaked at $13.3K in Q3 2024.
  • 184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.